Oxford Pharmascience Group plc has signed a license agreement with Bayer Consumer Care AG (BYR.L, BAYRY.PK, BAYZF.PK) in Basel to allow them to manufacture a calcium and Vitamin D soft chew using the Company's OXP chew technology. Pursuant to the deal, Bayer is being awarded a ten year license to manufacture a calcium and vitamin D soft chew product.
Nigel Theobald, Chief Executive, Oxford Pharmascience Group Plc, commented: "Partnering with Bayer is further evidence of our credibility in commercialising our technology platforms with major pharmaceutical companies. This is our first commercial relationship with a major global pharmaceutical company and their commitment and interest in our technologies is further evidence that our new strategic direction is working."
For comments and feedback: editorial@rttnews.com